Surgical Science Q2 2023: Industry/OEM sales in line but softness in Educational Products - Redeye

Redeye provides its initial take on Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’. We judge that notable positives from the report include c30% y/y Industry/OEM sales growth and EBITDA/EBIT aligning with our expectations. Notable negatives include net sales coming in c5% below our expectations due to c8% lower Educational Products sales than we estimated.

Länk till analysen i sin helhet: https://www.redeye.se/research/937798/surgical-science-q2-2023-industry-oem-sales-in-line-but-softness-in-educational-products?utm_source=finwire&utm_medium=RSS